Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-labelled, International, Multicenter, Dose Escalating, Phase I/II Study of SPC2996,an LNA Antisense Molecule Against Bcl-2, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia

NCT00285103 is registered in ClinicalTrials.gov with Santaris Pharma A/S as lead sponsor.

NCT NCT00285103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00285103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-labelled, International, Multicenter, Dose Escalating, Phase I/II Study of SPC2996,an LNA Antisense Molecule Against Bcl-2, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia
Lead sponsor
Santaris Pharma A/S
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2005
Completion date
December 31, 2007
Enrollment
46 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia